Objective  To assess the impact of statins combined with sorafenib (SRF) therapy on survival outcomes in patients with metastatic renal cell carcinoma (mRCC).

Methods  Clinical data of mRCC patients treated in the 908th Hospital of the Joint Security Force from November 2019 to November 2023 were retrospectively analyzed. They were categorized into statin group and non-statin group according to whether they used statins or not, and the differences in the primary endpoint of overall survival (OS), secondary endpoints of progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups.

Results  A total of 80 patients were included in the study, with 27 in the statin group and 53 in the non-statin group. There were no statistically significant differences in partial remission, stable disease, disease progression, and DCR between the two groups (P>0.05); complete remission and ORR were significantly higher in the statin group than in the non-statin group (P<0.05). Kaplan-Meier analysis showed that, compared with the non-statin group, the median PFS and OS of the statin group were prolonged, and the difference in median PFS between the two groups was statistically significant (P﹤0.05). In terms of safety, the incidence of other adverse events was similar in both groups (P>0.05).

Conclusion  Statins combined with SRF treatment regimen can improve ORR and DCR and prolong median PFS and OS in patients with mRCC.

1.罗丽莎, 栾航航, 郑航, 等. 中国1990—2019年归因于吸烟的前列腺癌、膀胱癌和肾癌疾病负担研究[J]. 中国循证医学杂志, 2022, 22(5): 530-536. [Luo LS, Luan HH, Zheng H, et al. Burden of prostate cancer, bladder cancer and kidney cancer attributable to smoking in China from 1990 to 2019[J]. Chinese Journal of Evidence-Based Medicine, 2022, 22(5): 530-536.] DOI: 10.7507/1672-2531.202201059.

2.曾圆圆, 刘磊. 转移性肾癌的治疗进展[J]. 华西医学, 2019, 34(9): 1068-1074. [Zeng YY, Liu L. Therapeutic progress of metastatic renal cell carcinoma[J]. West China Medical Journal, 2019, 34(9): 1068-1074.] DOI: 10.7507/1002-0179.201907153.

3.王直滔, 何玲芳, 楼永海. 1例培唑帕尼片致重度肝损伤的病例分析与药学监护[J]. 药物流行病学杂志, 2023, 32(1): 116-120. [Wang ZT, He LF, Lou YH. Case analysis and pharmaceutical care of one case of severe liver injury caused by pazopanib tablets[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(1): 116-120.] DOI: 10.19960/j.issn.1005-0698.202301018.

4.Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2): 125-134. DOI: 10.1056/NEJMoa060655.

5.Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial[J]. J Clin Oncol, 2009, 27(20): 3312-3318. DOI: 10.1200/JCO.2008.19.5511.

6.陈集志, 李博涵, 夏国际. 瑞舒伐他汀钙片致颞下颌关节脱位1例[J]. 药物流行病学杂志, 2024, 33(2): 236-240. [Chen JZ, Li BH, Xia GJ. One case of temporomandibular joint dislocation caused by rosuvastatin calcium tablets[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(2): 236-240.] DOI: 10.12173/j.issn.1005-0698.202312027.

7.王计亮, 李贵龙, 赵鹏, 等. 强化他汀联合增强型体外反搏治疗不稳定型心绞痛对复发率及Endocan-1、Vaspin水平的影响[J]. 药物流行病学杂志, 2022, 31(5): 291-295. [Wang JL, Li GL, Zhao P, et al. Effects of intensified statin combined with enhanced external counterpulsation on the recurrence rate and levels of endocan-1 and vaspin in patients with unstable angina pectoris[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(5): 291-295.] DOI: 10.19960/j.cnki.issn1005-0698.2022.05.001.

8.杨凯, 葛婷爱, 王晓琳, 等. 急性冠状动脉综合征患者经皮冠状动脉介入术前负荷剂量瑞舒伐他汀疗效的Meta分析[J]. 药物流行病学杂志, 2023, 32(7): 796-808. [Yang K, Ge TA, Wang XL, et al. Meta-analysis of the efficacy of pre-loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(7): 796-808.] DOI: 10.19960/j.issn.1005-0698.202307010.

9.彭倩雯, 徐斌, 张伟霞. 急性冠脉综合征患者原研与“带量采购”阿托伐他汀钙片疗效和安全性的回顾性比较[J]. 药物流行病学杂志, 2023, 32(4): 361-366. [Peng QW, Xu B, Zhang WX. Retrospective comparison of the efficacy and safety of the original and "volume-based procurement" atorvastatin calcium tablets in patients with acute coronary syndrome[J]. Chinese Journal of Pharmacoepidemiology , 2023, 32(4): 361-366.] DOI: 10.19960/j.issn.1005-0698.202304001.

10.曹志豪, 金鹏耀, 曾扬杰, 等. 他汀类药物抗肿瘤作用机制的研究进展[J]. 现代药物与临床, 2023, 38(7): 1798-1804. [Cao ZH, Jin PY, Zeng YJ, et al. Research progress on the anti-tumor mechanism of statins[J]. Drugs Clinic, 2023, 38(7): 1798-1804.] DOI: 10.7501/j.issn.1674-5515.2023.07.043.

11.Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates[J]. Nat Rev Clin Oncol, 2013, 10: 625e42. DOI: 10.1038/nrclinonc.2013.169.

12.Talesh GA, Trézéguet V, Merched A. Hepatocellular carcinoma and statins[J]. Biochemistry, 2020, 59(37): 3393-3400. DOI: 10.1021/acs.biochem.0c00476.

13.McKay RR, Lin X, Albiges L. Statins and survival outcomes in patients with metastatic renal cell carcinoma[J]. Eur J Cancer, 2016, 52: 155-162. DOI: 10.1016/j.ejca.2015.10.008.

14.桂有富, 刘昭, 邓若平, 等. 纳武单抗联合阿托伐他汀三线及以上方案治疗转移性肾细胞癌患者的临床疗效及其预后影响因素研究[J]. 临床泌尿外科杂志, 2024, 39(5): 424-430. [Gui YF, Liu Z, Deng RP, et al. Clinical efficacy and prognostic factors of nivolumab combined with atorvastatin in the third-line and above treatment of patients with metastatic renal cell carcinoma[J]. Journal of Clinical Urology, 2024, 39(5): 424-430.] DOI: 10.13201/j.issn.1001-1420.2024.05.010.

15.Lin JJ, Ezer N, Sigel K. The effect of statins on survival in patients with stage IV lung cancer[J]. Lung Cancer, 2016, 99: 137-142. DOI: 10.1016/j.lungcan.2016.07.006.  

16.Löfling LL, Støer NC, Andreassen BK. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a norwegian population-based cohort study[J]. Breast Cancer Res, 2023, 25(1): 101. DOI: 10.1186/s13058-023-01697-2.

17.Santoni M, Massari F, Matrana MR, et al. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma[J]. Eur J Cancer, 2022, 172: 191-198. DOI: 10.1016/j.ejca.2022.04.035.

18.Chou YC, Lin CH, Wong CS, et al. Statin use and the risk of renal cell carcinoma: national cohort study[J]. J Investig Med, 2020, 68(3): 776-781. DOI: 10.1136/jim-2019-001209.